|Bid||11.10 x 4000|
|Ask||11.28 x 1400|
|Day's Range||10.53 - 11.27|
|52 Week Range||7.85 - 22.80|
|Beta (3Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.00|
BERKELEY, Calif., Feb. 12, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel.
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BERKELEY, Calif., Jan. 29, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel.
NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...
How far off is Dynavax Technologies Corporation (NASDAQ:DVAX) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is Read More...
After a brutal fourth quarter to close out 2018, equities have started out on the right foot so far in 2019. Some soothing words from the Federal Reserve have helped the action in recent trading sessions, as has some progress on the trade talks between China and the United States. Helping tremendously are rallies in beaten-down sectors within the market.
Dynavax Technologies Corporation (DVAX), a leader in developing immunotherapies based on toll-like receptor (TLR) biology, and Sam’s Club, a leading membership warehouse club offering superior products, savings and services to millions of members in nearly 600 clubs, have teamed up to introduce HEPLISAV-B into Sam’s Club retail pharmacies nation-wide where pharmacists can immunize patients. HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. This is the first new hepatitis B vaccine in the United States in more than 25 years, and the only two-dose, one-month hepatitis B vaccine for adults.
BERKELEY, Calif., Jan. 03, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel.
After extended weakness, biotech stocks turned a corner along with the broader markets to close out the week. With just a session left, it looks less likely the sector ends in the black for the year. The ...
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
The Berkeley, California-based company said it had a loss of 65 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.